ATXA Therapeutics

28/02/2026

Rare is not rare. On , we'd like to help raise awareness of the > 300 million people worldwide living with a rare disease, along with their families and carers. Rare Disease Day Rare Diseases Ireland

27/02/2026

We are proud to announce that a new collaborative research article involving ATXA Therapeutics and our partners at Trinity College Dublin has been published this week in Nature Communications.

The paper, titled “Structural and Dynamic Insights into Agonist Recognition and Function of the Thromboxane A₂ Receptor”, presents cutting-edge findings on the structural determination and molecular dynamics of the thromboxane receptor (TP) – the cellular target of ATXA’s lead clinical candidate NTP42.

Read the full article here: https://www.nature.com/articles/s41467-026-69844-9.

The thromboxane A2 receptor (TP) is an important mediator of cardiovascular homeostasis. Here, authors report two structures of active TP-Gq bound to U46619 and I-BOP, revealing a molecular mechanism of TP activation and providing mechanistic insights into disease-associated TP mutations.

28/01/2026

ATXA Therapeutics is looking forward to attending the Pulmonary Vascular Research Institute (PVRI) Annual Congress 2026, taking place in Dublin, Ireland, from January 28 through February 1, 2026.

At the event, we will be presenting data strengthening the evidence for the involvement of its drug target, the thromboxane receptor (TP), in a range of cardiopulmonary diseases. These data strongly highlight the therapeutic potential of ATXA’s TP antagonist clinical candidate, NTP42, as a novel strategy to address the underlying pulmonary and cardiac dysfunction.

For more information, check out our website:

ATXA Therapeutics is looking forward to attending and presenting at the Pulmonary Vascular Research Institute (PVRI) Annual Congress 2026, taking place in Dublin, Ireland, from January 28 to February 1, 2026.The PVRI Annual Congress is a uniquely cross-disciplinary forum that brings together clinici...

23/12/2025

From all of us at ATXA Therapeutics, we wish you and yours a joyful and restful holiday season, and every success and happiness in 2026!

18/11/2025

ATXA Founder & CEO Therese Kinsella is joining leading global, public and private companies from the biotechnology & pharmaceutical sectors at Jefferies Global Healthcare Conference 2025 in London. Stay tuned for updates about the event with

31/03/2025

ATXA Therapeutics CEO & Founder Therese Kinsella was recently featured in the Business Post discussing the company's current fundraising and the plans to bring NTP42 through clinical trials in patients. Read more here...

ATXA, which is currently in the process of raising the €30 million, has been supported by Enterprise Ireland

28/02/2025

💜🌍 Today is Rare Disease Day! 🌍💜

Together, we stand with the 300 million people worldwide living with rare diseases. In uniting on this day we can raise awareness, advocate for change, and promote a more equitable future! ⚖️

Let’s use this moment to recognise and highlight the voices and stories of the rare disease community.

Share your story. Share your advocacy. Share your voice.

Go to our website to learn more: https://www.rarediseaseday.org/

24/02/2025

Rare is not rare. Taken together, over 300 million people worldwide are affected by a rare disease. on Friday, February 28 calls for equity in access to diagnosis, treatment & care for all people with a rare disease.
Rare Disease Day EURORDIS-Rare Diseases Europe

20/12/2024

On behalf of all of us here at ATXA Therapeutics, we wish you and yours a very happy and peaceful holiday season and the very best for 2025!

12/04/2024

Professor Therese Kinsella, Founder and CEO of ATXA Therapeutics, was the recipient of the main 2024 NovaUCD Innovation Award during an event held in the UCD University Club on April 11, 2024. These annual awards recognise excellence in innovation and of the successes achieved in the commercialisation of University College Dublin research over a number of years.

On receiving the award, Professor Kinsella said, “It is indeed a great honour for me to accept this Award from UCD both personally and on behalf of everyone on the ATXA team who have been part of our success journey so far.”

Read more at: https://www.ucd.ie/innovation/news-and-events/latest-news/2024-novaucd-innovation-awards/name,744339,en.html

29/02/2024

Have you got your social media pledge cards ready? 📝🌍

Available to download from our website, our pledge cards are written in 8 languages, allowing you to show your passion for Rare Disease Day, in your local contexts!

Download them today alongside our other resources by clicking on our website here: https://www.rarediseaseday.org/downloads/. Show your support for the international rare disease community today! 💻💡

26/02/2024

Why is it important to raise awareness?🤔

Bringing awareness to rare diseases is crucial as it sheds light on the specific challenges faced by those affected. From struggling to get a correct diagnosis due to limited knowledge among healthcare professionals to the financial burden of accessing expensive treatments, people often face uphill battles.

Moreover, the absence of tailored support networks can lead to feelings of isolation and misunderstanding. By sharing their stories and advocating for greater understanding, we can pave the way for improved resources, research, and ultimately, better quality of life. 💙